Comparing ways to give immunotherapy for advanced melanoma
Part of Cancer, Skin clinical trials.
This study tests a new way of giving a combination of two immunotherapy drugs (ipilimumab and nivolumab) for advanced melanoma. The drugs are given either into a vein or into the skin, to see if the skin injection works as well and causes fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have been diagnosed with a type of skin melanoma that has spread or cannot be removed with surgery.
- You need to be in reasonably good general health, able to take care of yourself, and have a life expectancy of at least 3 months.
- You must have at least one melanoma lesion on your skin that can be measured by CT or MRI scans.
- You need to have adequate liver, kidney, and bone marrow function based on blood tests done within 7 days before starting treatment.
- You must have a biopsy taken from a tumor before treatment starts, to help the doctors study the cancer.
- You must agree to use effective birth control during treatment and for a period after (men: 7 months, women: 23 weeks after the last dose).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.